Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 33,093 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trial of Nano-hydroxyapatite-Containing Toothpastes for Relief of Dentin Hypersensitivity

NCT04590040
Conditions
Dentin Sensitivity
Interventions
Placebo, 15% nano-HAP toothpaste, 5% KNO3 toothpaste
Other · Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
20 Years to 80 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Autosomal Dominant Polycystic Kidney Disease, ADPKD, Polycystic Kidney, Autosomal Dominant
Interventions
RGLS8429, Placebo
Drug
Lead sponsor
Regulus Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
21
States / cities
Mesa, Arizona • Los Angeles, California • New Haven, Connecticut + 17 more
Conditions
Ocular Hypertension, Open-angle Glaucoma
Interventions
Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Bedminster, New Jersey
Conditions
Longevity, GLP-1, Geroscience, Aging
Interventions
Metformin, Rapamycin, Naltrexone, Vitamin C
Drug · Dietary Supplement
Lead sponsor
AgelessRx
Industry
Eligibility
40 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence

NCT01468012
Conditions
Cocaine Dependence
Interventions
levodopa carbidopa and entacapone (LCE), Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Terminated Not applicable Interventional Accepts healthy volunteers

Restylane Silk Acne Scar Efficacy Evaluation Study

NCT02955381
Conditions
Acne, Acne Scars, AdverseEvent
Interventions
Restylane Silk, 1.0 ml, Saline, 1.0 ml
Device
Lead sponsor
Schweiger Dermatology, PLLC
Industry
Eligibility
22 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Type 2 Diabetes
Interventions
LY3502970, Dulaglutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
20
States / cities
Anaheim, California • Huntington Park, California • Los Angeles, California + 17 more
Conditions
Parkinson Disease
Interventions
K0706, Placebo
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Long Beach, California • Panorama City, California • DeLand, Florida + 2 more
Active, not recruiting Phase 1 Interventional

GDNF Gene Therapy for Multiple System Atrophy

NCT04680065
Conditions
Multiple System Atrophy
Interventions
AAV2-GDNF gene therapy, Sham (Placebo) Surgery
Biological · Procedure
Lead sponsor
Brain Neurotherapy Bio, Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Irvine, California • Boca Raton, Florida • Boston, Massachusetts + 4 more
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers

NCT01894165
Conditions
Molybdenum Cofactor Deficiency (MoCD), Rare Autosomal Recessive Disorder, Deficiency of Activity of Molybdenum-dependent Enzymes (Sulfite Oxidase [SOX], Xanthine Dehydrogenase, and Aldehyde Oxidase)
Interventions
ALXN1101, Placebo
Drug
Lead sponsor
Origin Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions
Paclitaxel, Carboplatin, Atezolizumab, Bevacizumab, Atezolizumab Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
127
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 101 more
Conditions
Gastric Cancer, Gastric Adenocarcinoma
Interventions
Rivoceranib, Placebo
Drug
Lead sponsor
Elevar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • Rogers, Arkansas • Detroit, Michigan + 2 more
Conditions
Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL, Anal HPV Infection, AIN
Interventions
Artesunate ointment, Placebo
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MEDI ΔM2-2 vaccine, Placebo vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Hidradenitis Suppurativa
Interventions
CFZ533, Placebo to CFZ533, LYS006, Placebo to LYS006, MAS825, Placebo to MAS825, LOU064 25mg, LOU064 100mg, Placebo to LOU064, VAY736, Placebo to VAY736
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
8
States / cities
Clearwater, Florida • Orange Park, Florida • Tampa, Florida + 5 more
Conditions
Rotator Cuff Tear
Interventions
0.5% bupivacaine, Normal Saline
Drug
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
18 Years to 90 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Healthy Volunteers
Interventions
Evinacumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cypress, California
Completed Phase 2 Interventional Accepts healthy volunteers

Clinical Trial of Pramipexole in Bipolar Depression

NCT00025792
Conditions
Bipolar Disorder
Interventions
Pramipexole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Withdrawn Not applicable Interventional Accepts healthy volunteers

Childhood Alopecia Areata Study Using the 308-nm Excimer Laser

NCT01736007
Conditions
Alopecia Areata
Interventions
308-nm excimer laser to alopecia patch, Liquid light guide tip on laser
Device
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
6 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Phoenix, Arizona
Completed Phase 1Phase 2 Interventional Results available

Transcranial Magnetic Stimulation for Tinnitus

NCT01104207
Conditions
Tinnitus
Interventions
repetitive transcranial magnetic stimulation (rTMS), placebo rTMS
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

NCT04829344
Conditions
Anesthesia, Local
Interventions
AG-920, Placebo
Drug
Lead sponsor
American Genomics, LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
McAllen, Texas
Conditions
Seborrheic Dermatitis, Papulopustular Rosacea
Interventions
PF-07038124, Placebo Ointment
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Severe Acute Respiratory Syndrome
Interventions
Camostat Mesilate, Standard of Care
Drug · Other
Lead sponsor
Alan Bryce
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Scottsdale, Arizona • Tucson, Arizona
Conditions
Glaucoma, Ocular Hypertension
Interventions
OTX-TP, Timolol
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fayetteville, Arkansas